Semaglutide 10mg injection: why this dose doesn't exist and what the licensed schedule actually looks like

Why there is no semaglutide 10mg injection, and what this tells you about unlicensed products

If you searched for a semaglutide 10mg injection, you may have come across a product claimed on social media, a grey-market website, or perhaps a compounding supplier. None of those match a licensed UK medicine. Wegovy's approved injection strengths are 0.25mg, 0.5mg, 1.0mg, 1.7mg, 2.4mg, and now 7.2mg, established through years of clinical trials and reviewed by the MHRA before any approval. A 10mg dose sits outside that range entirely.

This distinction matters practically. The MHRA has seized large quantities of fake weight-loss pens sold online, some containing insulin rather than semaglutide, and has warned publicly that unlicensed products present serious safety risks. If a seller is offering a semaglutide dose that does not appear in the licensed schedule, that is a clear warning sign. You can report any suspect sellers directly at the MHRA's Yellow Card scheme.

It is also worth a quick check: you can verify whether any UK online pharmacy dispensing weight-loss medicines holds a current GPhC registration at the GPhC pharmacy register. It takes under a minute and tells you a great deal about whether a supplier operates within UK law.

The actual Wegovy dose ladder, and the reasoning behind each step

Wegovy's titration schedule exists because semaglutide causes nausea, vomiting and other gastrointestinal effects that are most pronounced when the body first encounters the medicine. Starting at a low dose and increasing slowly lets most people adjust without having to stop treatment. The standard pathway moves from 0.25mg through 0.5mg, 1.0mg and 1.7mg before reaching the 2.4mg maintenance dose, with roughly four weeks at each level. Your prescriber decides the pace; the leaflet sets the floor. You can read more about how semaglutide injection dosing works and what each stage is designed to achieve.

In the STEP 1 trial, published in the New England Journal of Medicine, adults taking semaglutide 2.4mg weekly lost an average of around 15% of body weight over 68 weeks, alongside lifestyle changes. That is the evidence base the licensed dose is built on. The newer 7.2mg pen, approved by the MHRA in April 2026, produced around 20.7% average weight loss over 72 weeks in trials, a meaningful step up, though availability and suitability depend on individual clinical assessment.

There is no trial evidence supporting 10mg semaglutide injections, and no regulatory body has assessed such a dose for safety or effectiveness in the UK.

How to decide which licensed dose is right for you

The dose you end up on is not a decision made by reading a webpage, it is made by a prescriber who has reviewed your health history, current medications and weight. Factors that typically influence where treatment starts and how quickly it progresses include how well you tolerate the initial steps, any other medicines you take, and how your weight responds over time. For people who want to understand the landscape before a consultation, our overview of Wegovy's dose options sets out the full picture in straightforward terms.

If you are already on a different semaglutide product (Ozempic for diabetes management, for instance) switching to Wegovy for weight loss is a separate clinical decision that your prescriber needs to lead. The two licences are different, and the doses do not map onto each other directly. If you are currently on a lower strength and wondering what comes next, our page on the semaglutide 5mg injection explains where that fits within the broader treatment pathway. Similarly, the oral semaglutide tablet (Wegovy tablets, approved by the MHRA in June 2026) uses a completely separate dose schedule and is not interchangeable with the injection.

People considering the cost of treatment often ask whether a lower dose is cheaper and whether staying on one saves money. For a transparent look at what private Wegovy treatment involves financially, the cost context for Wegovy in the UK sets out what private pricing typically covers and what to watch for. For a prescription medicine, the clinical assessment matters as much as the price.

What happens if you cannot tolerate the standard titration

Some people find that side effects at a particular dose level are difficult to manage: persistent nausea, disrupted sleep, or gastrointestinal discomfort that does not settle within the expected window. This is the most common reason treatment does not progress to the maintenance dose at the standard pace. It does not automatically mean the medicine is wrong for you, it often means the titration needs to slow down, or that additional support around what and when you eat would help.

The NHS medicines page for semaglutide lists the side effects associated with the injection, when to seek urgent help, and what to discuss with your prescriber before stopping or pausing treatment. Stopping without clinical advice is rarely the right answer; a prescriber can adjust the plan. If you are earlier in the process and still working out the right amount to take, our guide to the semaglutide injection dose for weight loss covers how amounts are chosen and what the evidence says about each step. At nume, our clinical team is available seven days a week for exactly these conversations. For questions about the broader treatment journey, including what to expect at each stage, our Wegovy overview covers the full picture.

If you are ready to find out which treatment path is clinically right for you, start your free consultation and a GPhC-registered prescriber will review your case the same day.